Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03084965

Enrollment

1987

Registered

2017-03-21

Start date

2017-05-12

Completion date

2018-03-02

Last updated

2019-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type II Diabetes Mellitus

Brief summary

Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 99 Years

Healthy volunteers

Inclusion criteria

1. Outpatient equal to or more than 20 years of age. 2. T2DM patient initiated dapagliflozin after May 1st 2016 as a second line or third line oral anti-diabetic therapy, either as add-on or switching from one to another. Or initiating dapagliflozin as adjunctive therapy for T2DM subjects treated with insulin. 3. Completed follow-up of at least 6 months regardless of continuation on dapagliflozin therapy. 4. Will provide completed and signed written informed consents.

Exclusion criteria

1. Subjects with a history of SGLT2 inhibitor therapy other than dapagliflozin prior to Baseline. 2. Subjects with Type 1 diabetes. 3. Treatment with other investigational drugs concurrently during the retrospective data collection period.

Design outcomes

Primary

Measure	Time frame	Description
Change in HbA1c	6 months	To assess the change from baseline (time to initiate dapagliflozin\*) in HbA1c at 6 months

Countries

Taiwan

Outcome results